Gallowitsch H J, Mikosch P, Kresnik E, Unterweger O, Lind P
Department of Nuclear Medicine and Special Endocrinology, State Hospital Klagenfurt, Austria.
Invest Radiol. 2000 Aug;35(8):453-9. doi: 10.1097/00004424-200008000-00001.
Technetium-99m-((99m)Tc-) tetrofosmin, a cationic, lipophilic complex like (99m)Tc-sestamibi, has proved to be a potential tracer for parathyroid scintigraphy despite some differences in washout behavior from the thyroid gland. Previous results comparing a double-phase technique with single-proton emission computed tomography (SPECT) or with subtraction techniques demonstrated a high detection rate, especially when SPECT and subtraction techniques were used, whereas the double-phase protocol revealed only moderate results. In this study, a direct comparison was made between (99m)Tc-tetrofosmin/pertechnetate subtraction and SPECT to elucidate the optimal protocol for tetrofosmin parathyroid imaging.
Twenty-three patients who were biochemically suspected of parathyroid adenoma or hyperplasia due to primary or tertiary hyperparathyroidism were included in our study. In all patients, serum calcium, phosphate, and intact parathormone levels were analyzed in a single blood sample before (99m)Tc-tetrofosmin/pertechnetate subtraction scintigraphy and SPECT. Ultrasound of the neck was performed in all patients to exclude false-positive results due to thyroid adenomas. All patients underwent parathyroidectomy with intraoperative revision of all parathyroid glands, and the histological results were compared with preoperative findings.
Both imaging modalities, ie, subtraction scintigraphy and SPECT, correctly identified 20 of 23 (87%) histologically confirmed adenomas preoperatively. The positive predictive value was calculated to be 95% and 100%, respectively, for these two methods. Subtraction scintigraphy and SPECT showed concordant results in 19 patients (18 positive, 1 false-negative) and discordant results in 4 patients (2 positive with subtraction, 2 with SPECT). The combined use of subtraction scintigraphy and SPECT techniques revealed a sensitivity of 95.7% (22/23) and a positive predictive value of 95%. The whole procedure can be performed in less than 90 minutes per patient. Whereas subtraction scintigraphy tended to show more false-positive retentions due to thyroid adenomas, the interpretation of SPECT may be difficult in small adenomas with missing thyroid/parathyroid differential washout.
Both imaging modalities, subtraction scintigraphy with pertechnetate and SPECT, are highly sensitive methods for parathyroid adenoma localization with (99m)Tc-tetrofosmin. However, our study did demonstrate that a combination of both modalities can further improve the diagnostic accuracy. Especially in an endemic goiter area, additional ultrasound may be required to avoid false-positive results due to thyroid adenomas.
锝-99m(99mTc)替曲膦,一种类似于99mTc-甲氧基异丁基异腈的阳离子亲脂性复合物,尽管其从甲状腺清除的行为存在一些差异,但已被证明是甲状旁腺闪烁显像的一种潜在示踪剂。先前比较双期技术与单光子发射计算机断层扫描(SPECT)或减影技术的结果显示出较高的检出率,尤其是在使用SPECT和减影技术时,而双期方案的结果仅为中等。在本研究中,对99mTc-替曲膦/高锝酸盐减影与SPECT进行了直接比较,以阐明替曲膦甲状旁腺显像的最佳方案。
本研究纳入了23例因原发性或继发性甲状旁腺功能亢进而生化检查怀疑患有甲状旁腺腺瘤或增生的患者。在所有患者中,于99mTc-替曲膦/高锝酸盐减影闪烁显像和SPECT检查前采集一份血样,分析血清钙、磷和完整甲状旁腺激素水平。对所有患者进行颈部超声检查,以排除甲状腺腺瘤导致的假阳性结果。所有患者均接受甲状旁腺切除术,并在术中对所有甲状旁腺进行检查,将组织学结果与术前检查结果进行比较。
两种成像方式,即减影闪烁显像和SPECT,术前均正确识别出23例组织学确诊腺瘤中的20例(87%)。这两种方法的阳性预测值分别计算为95%和100%。减影闪烁显像和SPECT在19例患者中结果一致(18例阳性,1例假阴性),在4例患者中结果不一致(2例减影阳性,2例SPECT阳性)。减影闪烁显像和SPECT技术联合使用显示敏感性为95.7%(22/23),阳性预测值为95%。整个过程每位患者可在90分钟内完成。减影闪烁显像由于甲状腺腺瘤往往显示更多的假阳性滞留,而对于甲状腺/甲状旁腺清除差异不明显的小腺瘤,SPECT的解读可能会有困难。
高锝酸盐减影闪烁显像和SPECT这两种成像方式都是使用99mTc-替曲膦定位甲状旁腺腺瘤的高敏感方法。然而,我们的研究确实表明两种方式联合使用可进一步提高诊断准确性。特别是在地方性甲状腺肿地区,可能需要额外的超声检查以避免甲状腺腺瘤导致的假阳性结果。